News Releases & Statements
News Releases & Statements
Subaru of America Dedicates June to Sharing Hope and Warmth with Those Battling Cancer
Posted On: June 1, 2021 Read More
The Leukemia & Lymphoma Society launches Impact Research grants to help underserved patients access to clinical trials
Posted On: May 6, 2021Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials.
Read More
Covid-19 Vaccine Safety Among Blood Cancer Patients
Posted On: April 23, 2021Update: October 8, 2021
Read More
LLS TAP announces five new investments supporting next generation immunotherapies
Posted On: April 22, 2021RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.
Read More
LLS Statement about UK Study on Vaccine Efficacy in Cancer Patients
Posted On: April 20, 2021Findings from the recent King’s College London study show that three weeks after one dose of the Pfizer vaccine, an antibody response was found in 39% of solid cancer patients and just 13% of people with blood cancer, compared to 95% in healthy individuals. There was a promising report that three out of five (60%) blood cancer patients studied had an immune response after the second dose, but there were not enough blood cancer patients studied for full clinical interpretation.
Read More
LLS Statement on Anti-Asian Violence and Discrimination
Posted On: April 20, 2021The Leukemia & Lymphoma Society condemns violence and discrimination against members of the Asian, Asian American, and Pacific Islander community, which has intensified because of the pandemic and misinformation about how COVID-19 spreads.
As an organization committed to scientific research, advocacy, education, and support, we must fight injustice and racism with the same urgency as we fight blood cancers. We can only accomplish our work to alleviate healthcare disparities if we fight inequity in all its forms.
Read More
Statement on Recent mRNA-based COVID-19 Vaccines Studies for Blood Cancer Patients
Posted On: April 20, 2021The Leukemia & Lymphoma Society (LLS) has heard from blood cancer patients and caregivers who are concerned about new research suggesting that mRNA-based COVID-19 vaccines may offer less protection for people with certain blood cancers.
Read More
FDA Approves Isatuximab for Relapsed/Refractory Multiple Myeloma
Posted On: April 20, 2021Rye Brook, N.Y., April 20, 2021 - The U.S. Food and Drug Administration (FDA) approved isatuximab (Sarclisa) in combination with carfilzomib and dexamethasone to treat adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Read MoreMedia Requests
Please send all media-related inquiries and interview requests to mediarelations@lls.org. An LLS representative will respond as soon as possible.